Total Payments
$10,798
2024 Payments
$2,164
Companies
60
Transactions
583
Medicare Patients
14,678
Medicare Billing
$4.6M
Payment Breakdown by Category
Food & Beverage$10,678 (98.9%)
Education$120.82 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,678 | 577 | 98.9% |
| Education | $120.82 | 6 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,261 | 70 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $930.94 | 54 | $0 (2024) |
| Genentech USA, Inc. | $869.41 | 64 | $0 (2024) |
| Merck Sharp & Dohme LLC | $707.84 | 38 | $0 (2024) |
| PFIZER INC. | $623.77 | 45 | $0 (2024) |
| Janssen Biotech, Inc. | $587.76 | 30 | $0 (2024) |
| EMD Serono, Inc. | $506.52 | 26 | $0 (2024) |
| ASD Specialty Healthcare, LLC | $381.86 | 4 | $0 (2024) |
| GENZYME CORPORATION | $376.75 | 19 | $0 (2024) |
| Celgene Corporation | $370.94 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,164 | 78 | Novartis Pharmaceuticals Corporation ($226.99) |
| 2023 | $1,373 | 58 | Novartis Pharmaceuticals Corporation ($209.00) |
| 2022 | $1,138 | 59 | Novartis Pharmaceuticals Corporation ($125.40) |
| 2021 | $711.95 | 36 | Novartis Pharmaceuticals Corporation ($108.83) |
| 2020 | $338.89 | 20 | Janssen Biotech, Inc. ($37.97) |
| 2019 | $1,437 | 94 | Genentech USA, Inc. ($169.74) |
| 2018 | $1,791 | 122 | Novartis Pharmaceuticals Corporation ($333.58) |
| 2017 | $1,846 | 116 | Genentech USA, Inc. ($295.13) |
All Payment Transactions
583 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: BioOncology | ||||||
| 12/19/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Oncology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $9.99 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: Immunology | ||||||
| 11/25/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $15.60 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/20/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.02 | General |
| 11/16/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.26 | General |
| Category: Oncology | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.02 | General |
| Category: Oncology | ||||||
| 11/05/2024 | ASD Specialty Healthcare, LLC | — | Food and Beverage | In-kind items and services | $103.13 | General |
| 11/04/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Cardinal Health 108 LLC | — | Food and Beverage | In-kind items and services | $159.48 | General |
| 10/29/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $18.37 | General |
| 10/09/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.43 | General |
| 10/07/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: Oncology | ||||||
| 10/03/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $9.89 | General |
| 09/26/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $104.30 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: Oncology | ||||||
| 09/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $29.24 | General |
| 09/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $0.76 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: BioOncology | ||||||
| 08/30/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.10 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 70 | 4,025 | 109,975 | $5.1M | $1.3M |
| 2022 | 73 | 3,802 | 118,392 | $6.0M | $1.6M |
| 2021 | 66 | 3,715 | 108,447 | $4.2M | $1.2M |
| 2020 | 58 | 3,136 | 76,530 | $2.1M | $524,464 |
Total Patients
14,678
Total Services
413,344
Medicare Billing
$4.6M
Procedure Codes
268
All Medicare Procedures & Services
268 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 16,200 | $2.1M | $698,180 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 352 | 1,556 | $311,200 | $145,984 | 46.9% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 51 | 63 | $378,000 | $68,426 | 18.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 69 | 657 | $331,128 | $64,590 | 19.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 25 | 36,750 | $158,476 | $30,797 | 19.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 51 | 64 | $49,920 | $26,313 | 52.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 141 | $280,692 | $18,817 | 6.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 54 | 110 | $166,870 | $18,465 | 11.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 198 | 273 | $40,950 | $18,037 | 44.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 64 | 1,522 | $114,076 | $17,817 | 15.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 16 | 11,310 | $87,687 | $15,543 | 17.7% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 25 | 688 | $102,512 | $11,986 | 11.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 246 | 1,085 | $79,205 | $11,202 | 14.1% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 64 | 124 | $153,884 | $10,108 | 6.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 350 | 1,186 | $28,464 | $9,948 | 34.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $26,950 | $9,661 | 35.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 33 | 188 | $45,496 | $9,150 | 20.1% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 44 | 271 | $45,257 | $6,512 | 14.4% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 234 | 1,013 | $43,559 | $6,411 | 14.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 99 | $21,186 | $4,584 | 21.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 55 | 160 | $24,000 | $4,405 | 18.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 27 | 189 | $21,735 | $4,069 | 18.7% |
| 85007 | Microscopic examination for white blood cells with manual cell count | Office | 2023 | 234 | 1,012 | $27,324 | $3,758 | 13.8% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 11 | 70 | $15,260 | $2,939 | 19.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 30 | 131 | $18,340 | $2,835 | 15.5% |
About Dr. Justin Floyd, DO
Dr. Justin Floyd, DO is a Medical Oncology healthcare provider based in O Fallon, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629164678.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Justin Floyd, DO has received a total of $10,798 in payments from pharmaceutical and medical device companies, with $2,164 received in 2024. These payments were reported across 583 transactions from 60 companies. The most common payment nature is "Food and Beverage" ($10,678).
As a Medicare-enrolled provider, Floyd has provided services to 14,678 Medicare beneficiaries, totaling 413,344 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 268 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location O Fallon, IL
- Active Since 10/05/2006
- Last Updated 12/08/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1629164678
Products in Payments
- OPDIVO (Biological) $716.74
- KEYTRUDA (Biological) $632.23
- IMBRUVICA (Drug) $323.42
- TECENTRIQ (Biological) $230.09
- AFINITOR (Drug) $202.58
- PROMACTA (Drug) $198.30
- Perjeta (Biological) $194.66
- Revlimid (Drug) $190.67
- Neulasta (Biological) $188.48
- SUTENT (Drug) $174.36
- BAVENCIO (Drug) $173.42
- IBRANCE (Drug) $161.62
- ZEJULA (Drug) $161.50
- Stivarga (Drug) $158.93
- TECVAYLI (Biological) $143.32
- SARCLISA (Biological) $141.50
- TASIGNA (Drug) $138.51
- DARZALEX (Biological) $132.19
- INLYTA (Drug) $131.43
- VENCLEXTA (Biological) $129.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.